Areva to begin US trial of cancer-fighting isotope

January 24, 2011

A subsidiary of the French nuclear giant Areva said Monday it had received US clearance to begin a clinical trial of an isotope that targets cancer cells.

"Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments," Areva Med said in a statement.

"This innovative approach, known as alpha radio-immunotherapy, specifically pinpoints and destroys while limiting to healthy cells."

The phase one trial, which assesses safety, will begin in 2011 and take about two years. The treatment's primary target will be pancreatic cancer, a company spokesman said.

"This landmark FDA authorization is a very important step that could lead to a potential treatment for very aggressive and lethal cancers," said Jacques Besnainou, CEO of Areva North America.

A spokeswoman declined to elaborate on the authorization, saying the agency does not comment on that are under way or about to begin.

Areva announced last year the construction of a facility to produce lead-212 in the Limousin region of France.

Related Stories

Recommended for you

Fighting cancer with the power of immunity

October 24, 2016

Harnessing the body's own immune system to destroy tumors is a tantalizing prospect that has yet to realize its full potential. However, a new advance from MIT may bring this strategy, known as cancer immunotherapy, closer ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jan 25, 2011
This article does not mention how the isotope is administred. So how does the treatment manage to target cancer cells and nothing else?
BTW it is not the lead isotope that attacks cancer, it is the alpha particle radiation that kills the cells.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.